PHASE 2/3 OPEN LABEL RANDOMIZED STUDY OF TELISOTUZUMAB ADIZUTECAN IN COMBINATION WITH FOLFOX COMPARED TO STANDARD OF CARE IN SUBJECTS WITH FIRST- LINE METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA - ANDROMETA-PDAC-288
- Registry ID
- M25-288
- Source registry
- HEALTH_CANADA
- Status
- Pending
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- ABBVIE CORPORATION
- Last update
- 2026-05-06
Conditions
- METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Related clinical trials
- A PHASE 2B/3, RANDOMIZED, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY, SAFETY,
AND TOLERABILITY OF PONSEGROMAB (PF-06946860) COMPARED WITH PLACEBO BOTH WITH BACKGROUND
FIRST-LINE CHEMOTHERAPY IN ADULT PARTICIPANTS WITH CACHEXIA AND METASTATIC PANCREATIC DUCTAL
ADENOCARCINOMA
- MOUNTAINTAP-30: A RANDOMIZED, PHASE 2/3 STUDY COMPARING BMS-986504 IN
COMBINATION WITH NAB-PACLITAXEL AND GEMCITABINE VERSUS PLACEBO IN COMBINATION
WITH NAB-PACLITAXEL AND GEMCITABINE IN PARTICIPANTS WITH UNTREATED METASTATIC
PANCREATIC DUCTAL ADENOCARCINOMA HARBORING HOMOZYGOUS MTAP DELETION
- A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER, PHASE 3 TRIAL
OF QUEMLICLUSTAT AND CHEMOTHERAPY VERSUS PLACEBO AND CHEMOTHERAPY IN
PATIENTS WITH TREATMENT-NAIVE METASTATIC PANCREATIC DUCTAL
ADENOCARCINOMA
- A PHASE II OPEN-LABEL, MULTI-CENTER STUDY OF MEDI4736 EVALUATED AS SINGLE AGENT OR IN COMBINATION WITH TREMELIMUMAB IN PATIENTS WITH METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
View on source registry